REPLIGEN AND THE STANLEY MEDICAL RESEARCH INSTITUTE EXPAND DEVELOPMENT AGREEMENT

Repligen Corporation (Nasdaq: RGEN) today announced that the Company has entered into an expanded development agreement with the Stanley Medical Research Institute under which Repligen will receive approximately $1,000,000 in funding for a Phase 2 clinical trial of uridine in bipolar depression. Pending approval by the FDA, the Phase 2 study will be a multi-center, dose escalating study in which 80 patients will receive either an oral formulation of uridine or a placebo for 6 weeks. Patients will be evaluated for the safety and effectiveness of uridine on the symptoms of bipolar depression.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-21-2005/0004174572&EDATE=)